CMV423

CMV423 (2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide) is an experimental antiviral drug that has been studied for the treatment of cytomegalovirus (CMV) infection^[1] and human herpesvirus 6 (HHV-6) infection.^[2][3] The drug was investigated by Sanofi-Aventis, but its development was discontinued by 2018 before entering clinical trials.^[2]

Other namesCMV-423; RPR-111423

Legal status

• Investigational

CAS Number

• 186829-19-6 ^Y

PubChem CID

• 489128

Quick facts Clinical data, Other names ...

CMV423

Clinical data
Other names	CMV-423; RPR-111423
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-Chloro-3-(pyridin-3-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide
CAS Number	186829-19-6 Y
PubChem CID	489128
ChemSpider	428515
UNII	PDX37M872C
CompTox Dashboard (EPA)	DTXSID40333187
Chemical and physical data
Formula	C14H14ClN3O
Molar mass	275.74 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1cc(cnc1)c2c(c(c3n2CCCC3)C(=O)N)Cl
InChI InChI=1S/C14H14ClN3O/c15-12-11(14(16)19)10-5-1-2-7-18(10)13(12)9-4-3-6-17-8-9/h3-4,6,8H,1-2,5,7H2,(H2,16,19) Key:KNGXENHWYNLKBU-UHFFFAOYSA-N

Close